Review
Adverse Skin Effects of Imatinib, a Tyrosine Kinase Inhibitor
Efectos adversos cutáneos del imatinib (inhibidor de la tirosín cinasa)
Leído
21760
Vecesse ha leído el artículo
4003
Total PDF
17757
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 6 | 128 | 10 | 138 |
| 2025 5 | 639 | 67 | 706 |
| 2025 4 | 673 | 101 | 774 |
| 2025 3 | 569 | 69 | 638 |
| 2025 2 | 597 | 69 | 666 |
| 2025 1 | 464 | 57 | 521 |
| 2024 12 | 448 | 39 | 487 |
| 2024 11 | 349 | 80 | 429 |
| 2024 10 | 240 | 61 | 301 |
| 2024 9 | 284 | 45 | 329 |
| 2024 8 | 368 | 61 | 429 |
| 2024 7 | 374 | 62 | 436 |
| 2024 6 | 266 | 59 | 325 |
| 2024 5 | 270 | 61 | 331 |
| 2024 4 | 198 | 35 | 233 |
| 2024 3 | 269 | 46 | 315 |
| 2024 2 | 306 | 39 | 345 |
| 2024 1 | 255 | 52 | 307 |
| 2023 12 | 279 | 34 | 313 |
| 2023 11 | 301 | 39 | 340 |
| 2023 10 | 287 | 46 | 333 |
| 2023 9 | 299 | 48 | 347 |
| 2023 8 | 190 | 32 | 222 |
| 2023 7 | 184 | 45 | 229 |
| 2023 6 | 183 | 27 | 210 |
| 2023 5 | 201 | 35 | 236 |
| 2023 4 | 111 | 28 | 139 |
| 2023 3 | 114 | 32 | 146 |
| 2023 2 | 88 | 19 | 107 |
| 2022 1 | 89 | 32 | 121 |
| 2022 12 | 117 | 40 | 157 |
| 2022 11 | 70 | 31 | 101 |
| 2022 10 | 79 | 33 | 112 |
| 2022 9 | 92 | 40 | 132 |
| 2022 8 | 71 | 47 | 118 |
| 2022 7 | 66 | 45 | 111 |
| 2022 6 | 68 | 42 | 110 |
| 2022 5 | 161 | 46 | 207 |
| 2022 4 | 205 | 45 | 250 |
| 2022 3 | 213 | 70 | 283 |
| 2022 2 | 221 | 38 | 259 |
| 2021 1 | 237 | 60 | 297 |
| 2021 12 | 185 | 58 | 243 |
| 2021 11 | 204 | 68 | 272 |
| 2021 10 | 249 | 69 | 318 |
| 2021 9 | 171 | 72 | 243 |
| 2021 8 | 246 | 71 | 317 |
| 2021 7 | 205 | 56 | 261 |
| 2021 6 | 203 | 33 | 236 |
| 2021 5 | 191 | 30 | 221 |
| 2021 4 | 543 | 51 | 594 |
| 2021 3 | 245 | 45 | 290 |
| 2021 2 | 226 | 42 | 268 |
| 2020 1 | 151 | 42 | 193 |
| 2020 12 | 156 | 39 | 195 |
| 2020 11 | 88 | 28 | 116 |
| 2020 10 | 141 | 42 | 183 |
| 2020 9 | 111 | 31 | 142 |
| 2020 8 | 82 | 37 | 119 |
| 2020 7 | 101 | 27 | 128 |
| 2020 6 | 76 | 39 | 115 |
| 2020 5 | 60 | 32 | 92 |
| 2020 4 | 632 | 39 | 671 |
| 2020 3 | 53 | 36 | 89 |
| 2020 2 | 2 | 10 | 12 |
| 2020 1 | 0 | 5 | 5 |
| 2019 12 | 3 | 15 | 18 |
| 2019 11 | 0 | 9 | 9 |
| 2019 10 | 1 | 6 | 7 |
| 2019 9 | 5 | 14 | 19 |
| 2019 8 | 0 | 11 | 11 |
| 2019 7 | 0 | 29 | 29 |
| 2019 6 | 2 | 31 | 33 |
| 2019 5 | 0 | 39 | 39 |
| 2019 4 | 1 | 64 | 65 |
| 2019 3 | 2 | 11 | 13 |
| 2019 2 | 1 | 11 | 12 |
| 2019 1 | 0 | 10 | 10 |
| 2018 12 | 4 | 0 | 4 |
| 2018 11 | 2 | 0 | 2 |
| 2018 10 | 5 | 0 | 5 |
| 2018 9 | 2 | 8 | 10 |
| 2018 8 | 0 | 25 | 25 |
| 2018 7 | 0 | 29 | 29 |
| 2018 6 | 0 | 17 | 17 |
| 2018 5 | 0 | 19 | 19 |
| 2018 4 | 0 | 17 | 17 |
| 2018 3 | 6 | 16 | 22 |
| 2018 2 | 222 | 26 | 248 |
| 2018 1 | 162 | 33 | 195 |
| 2017 12 | 176 | 16 | 192 |
| 2017 11 | 114 | 26 | 140 |
| 2017 10 | 121 | 23 | 144 |
| 2017 9 | 95 | 24 | 119 |
| 2017 8 | 110 | 28 | 138 |
| 2017 7 | 103 | 37 | 140 |
| 2017 6 | 88 | 34 | 122 |
| 2017 5 | 77 | 27 | 104 |
| 2017 4 | 75 | 10 | 85 |
| 2017 3 | 76 | 33 | 109 |
| 2017 2 | 54 | 35 | 89 |
| 2016 1 | 57 | 26 | 83 |
| 2016 12 | 64 | 18 | 82 |
| 2016 11 | 123 | 32 | 155 |
| 2016 10 | 136 | 29 | 165 |
| 2016 9 | 94 | 28 | 122 |
| 2016 8 | 3 | 9 | 12 |
| 2016 7 | 9 | 8 | 17 |
| 2016 6 | 14 | 3 | 17 |
| 2016 5 | 4 | 1 | 5 |
| 2016 4 | 12 | 2 | 14 |
| 2016 3 | 12 | 3 | 15 |
| 2016 2 | 14 | 21 | 35 |
| 2015 1 | 11 | 5 | 16 |
| 2015 12 | 21 | 11 | 32 |
| 2015 11 | 14 | 3 | 17 |
| 2015 10 | 18 | 2 | 20 |
| 2015 9 | 17 | 5 | 22 |
| 2015 8 | 10 | 2 | 12 |
| 2015 7 | 115 | 10 | 125 |
| 2015 6 | 73 | 10 | 83 |
| 2015 5 | 74 | 7 | 81 |
| 2015 4 | 54 | 16 | 70 |
| 2015 3 | 65 | 3 | 68 |
| 2015 2 | 95 | 7 | 102 |
| 2015 1 | 39 | 8 | 47 |
| 2014 12 | 34 | 9 | 43 |
| 2014 11 | 40 | 5 | 45 |
| 2014 10 | 61 | 14 | 75 |
| 2014 9 | 23 | 4 | 27 |
Mostrar todo
